These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28427281)

  • 1. The Servier oncology pipeline in 2017.
    Therasse P; Perron B; Novack SA; Abastado JP
    Future Oncol; 2017 Jul; 13(17):1527-1536. PubMed ID: 28427281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Servier's pipeline in oncology: moving from research to patients.
    Therasse P; Abastado JP
    Future Oncol; 2016 Mar; 12(5):589-94. PubMed ID: 26764971
    [No Abstract]   [Full Text] [Related]  

  • 3. Servier in oncology: bringing innovation to patients.
    Bertrand CP
    Future Oncol; 2019 Jul; 15(19):2191-2197. PubMed ID: 31146594
    [No Abstract]   [Full Text] [Related]  

  • 4. Discontinued drugs in 2010: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
    Mukherji D; Pettengell R
    Expert Opin Pharmacother; 2010 Aug; 11(11):1915-23. PubMed ID: 20569087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RACE to accelerate drug development for children with cancer.
    Pearson ADJ; Karres D; Reaman G; DuBois SG; Knox L; Scobie N; Vassal G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):714-716. PubMed ID: 32822672
    [No Abstract]   [Full Text] [Related]  

  • 7. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
    Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
    Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
    Jamal-Hanjani M; Pettengell R
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1441-8. PubMed ID: 21905966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Providing innovative solutions in a single pill: Servier's portfolio in hypertension.
    Mourad JJ; Guillerm JC
    Future Cardiol; 2016 Sep; 12(5):515-20. PubMed ID: 27503672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.
    Boyle EM; Morschhauser F
    Expert Opin Drug Saf; 2015 Apr; 14(4):601-7. PubMed ID: 25716061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.
    Zinzani PL; Corradini P; Martelli M; Minotti G; Oliva S; Spina M; Barosi G; Tura S
    Eur J Haematol; 2016 Dec; 97(6):554-561. PubMed ID: 27124765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
    Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
    Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathology in oncology--the AstraZeneca perspective.
    Campbell DA; Carmichael J; Chopra R
    Pharmacogenomics; 2004 Dec; 5(8):1167-73. PubMed ID: 15584883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry.
    Cottens S; Eaton M; Fuhr J; Geary S; Johnson DS; Li G; Raveglia L; Robertson GM; Westwell A
    Future Med Chem; 2011 Nov; 3(15):1863-72. PubMed ID: 22023030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
    Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
    Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.
    Jahangiri S; Friedberg J; Barr P
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):367-83. PubMed ID: 24960458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New trends in the diagnosis and treatment of malignant lymphoma].
    Tobinai K
    Nihon Igaku Hoshasen Gakkai Zasshi; 2003 Feb; 63(3):81-8. PubMed ID: 12692961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical update on oncology treatments and trends.
    Brooks BJ
    Am J Manag Care; 2006 Mar; 12(3 Suppl):S43-70; quiz S71-2. PubMed ID: 16551203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.
    Costa LJ
    Cancer Treat Rev; 2007 Feb; 33(1):78-84. PubMed ID: 17161912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
    Choe H; Ruan J
    Oncology (Williston Park); 2016 Sep; 30(9):847-58. PubMed ID: 27633417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.